Trials: Moderate to Severe Nail Psoriasis

Phase 3 N=99 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis · Moderate to Severe Nail Psoriasis

Primary: The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28. — 0.042; 0.255 proportion of subjects — p=0.00311

Sun Pharmaceutical Industries Limited Results Jun 2025 5.1% serious AE View details

Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

Psoriatic Nail · Psoriasis Vulgaris · Psoriasis

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

University of Alabama at Birmingham Results Jul 2021 8.3% serious AE View details

N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis

Nail Psoriasis

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

University of Utah Results Aug 2019 0.0% serious AE View details

Phase 3 N=198 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Moderate to Severe Nail Psoriasis

Primary: Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment — -38.4; -46.1; -11.7 percent change — p=<0.0001

Novartis Pharmaceuticals Results Mar 2018 8.8% serious AE View details

Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement

Psoriasis

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Amgen Results Nov 2013 2.5% serious AE View details

Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis

Palmo-plantar Psoriasis

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Innovaderm Research Inc. Results Oct 2018 5.0% serious AE View details

Phase 4 N=72 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Nail Psoriasis · Plaque Psoriasis

Primary: Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score for Target Fingernail — -4.32; -4.36 units on a scale — p=<0.0001

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2010 2.8% serious AE View details

Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…

Takeda Results Sep 2023 0.4% serious AE View details

Phase 3 N=159 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Psoriasis

Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants

Merck Sharp & Dohme LLC Results Dec 2010 1.3% serious AE View details

Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Nail Psoriasis · Plaque Psoriasis

Primary: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 — 3.4; 46.6 percentage of participants…

AbbVie Results Feb 2017 4.7% serious AE View details

N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Primary: Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12 — -74.6 percent change

AbbVie (prior sponsor, Abbott) Results Aug 2014 1.0% serious AE View details

Phase 4 N=55 Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

Nail Psoriasis · Nail Diseases

Primary: Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis — 2.5 mg/mL

Weill Medical College of Cornell University Results Mar 2024 0.0% serious AE View details

Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants

Psoriasis Treatment Center of Central New Jersey Results Jan 2019 4.4% serious AE View details

Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Psoriasis

Primary: Clinical Success — 18; 3 participants — p=0.0003

Sun Pharmaceutical Industries, Inc. Results Aug 2014 0.0% serious AE View details

Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Palmoplantar Psoriasis

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Innovaderm Research Inc. Results Sep 2010 12.5% serious AE View details

Phase 4 N=6 A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

Nail Psoriasis

Primary: Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. — 2 Participants who experienced improvement

University of Alabama at Birmingham Results Jan 2025 0.0% serious AE View details

Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Palmoplantar Pustular Psoriasis

Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722

Novartis Pharmaceuticals Results Jan 2019 12.5% serious AE View details

Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Amgen Results Sep 2018 2.4% serious AE View details

Phase 4 N=39 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Psoriasis

Primary: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1 — 24 Participants

Icahn School of Medicine at Mount Sinai Results Jul 2019 0.0% serious AE View details

Phase 2 N=129 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

Psoriasis

Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495

Ziarco Pharma Ltd Results Jul 2021 3.9% serious AE View details

N/A N=486 Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Plaque Psoriasis

Primary: Mean Change From Baseline in Percent Body Surface Area (BSA) Score at Month 4 — 28.1; 29.21; -6.79; -6.38 Percent BSA — p=0.35

Pfizer Results Oct 2021 View details

Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Innovaderm Research Inc. Results Dec 2010 0.0% serious AE View details

Phase 2 N=313 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Psoriasis

Primary: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 — 25; 44; 41; 45 Participants — p=<0.0001

Bond Avillion 2 Development LP Results Aug 2021 3.0% serious AE View details

Phase 3 N=33 Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis

Nail Psoriasis

Primary: Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI) at 24 Weeks — 27.2; 27.4; 14.4; 20.4 units on a scale

Yin-ku Lin Results Aug 2019 0.0% serious AE View details

Phase 3 N=202 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Psoriasis

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001

Novartis Pharmaceuticals Results Oct 2017 4.0% serious AE View details

Phase 4 N=273 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

Plaque Psoriasis · Psoriasis

Primary: Percentage of Participants Achieving a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 24 — 78.2; 59.9 Percentage of participants…

Pfizer Results Apr 2012 2.6% serious AE View details

Phase 2 N=46 Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Psoriasis · Plaque Psoriasis

Primary: Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs — 27; 32; 0; 0 TEAEs

MetrioPharm AG Results Jan 2019 0.0% serious AE View details

Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Psoriasis

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Amgen Results Sep 2019 2.0% serious AE View details

Phase 3 N=31 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails

Nail Psoriasis

Primary: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week…

Chang Gung Memorial Hospital Results Sep 2012 0.0% serious AE View details

Phase 2 N=267 Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Psoriasis

Primary: The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85…

Bristol-Myers Squibb Results Nov 2020 1.5% serious AE View details

Clinical Trial Search

Phase 3 N=99 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis

Phase 3 N=198 Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement

Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis

Phase 4 N=72 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Phase 3 N=159 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Phase 4 N=55 Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

Phase 4 N=6 A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Phase 4 N=39 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Phase 2 N=129 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

N/A N=486 Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis

Phase 2 N=313 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Phase 3 N=33 Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis

Phase 3 N=202 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Phase 4 N=273 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

Phase 2 N=46 Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Phase 3 N=31 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails

Phase 2 N=267 Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis